|
![]() |
SYS-CON.TV Webcasts
Comments
Did you read today's front page stories & breaking news?
SYS-CON.TV
|
Today's Top SOA Links
From the Wires
Mammography World Markets
By: PR Newswire
Jan. 10, 2013 08:44 AM
NEW YORK, Jan. 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p098222/Mammography-World-Markets.html#utm_s... Breast cancer is the most common type of cancer in women, affecting one in eight during their lives. Mammography is the most valuable method for detecting potentially cancerous anomalies in the breast. As such, the mammography equipment segment is poised for a major new phase of growth fueled by the availability of new technologies. Mammograms are images of the breast tissue produced from low radiation X-rays. The three types of mammography systems are: 1) analog systems, 2) computed tomography (CR) systems and 3) full-field digital mammography (FFDM). The analog systems are the conventional types, and they use X-ray films for capturing the breast images. The CR systems are also film-based, but are retrofitted with digital detectors. In FFDM, the X-ray film is replaced by solid-state detectors that convert X-rays into electrical signals. Digital tomosynthesis is a new technology with improved diagnostic capabilities over standard digital mammography. Moreover, scintimammography (nuclear medicine breast imaging) is an additional breast exam available. This TriMark Publications report thoroughly reviews: 1) existing and emerging mammography technologies, 2) known risk factors for breast cancer, 3) breast cancer treatments and drugs, 4) types of mastectomy procedures, 5) breast reconstruction surgery, and 6) funding for breast cancer research. The study examines almost all of the companies known to be marketing, manufacturing or developing mammography equipment and breast cancer therapies in the world. Each company is discussed in extensive depth with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included. TABLE OF CONTENTS 1. Overview 91.1 Statement of Report 9 1.2 Scope of This Report 10 1.3 Methodology 10 1.4 Executive Summary 11 2. Breast Cancer: An Overview 142.1 Anatomy of a Normal Breast 142.1.1 Abnormalities in Breast 142.1.2 Selected Types of Breast Cancer 152.1.3 Non-Invasive Breast Cancers 152.1.4 Invasive Breast Cancers 162.1.5 Other Benign Structures Found in the Breast in Screening Mammography 192.1.6 Other Breast Anomalies Detected During Diagnostic Mammography 20 3. Global and Regional Data on Breast Cancer 22 3.1 Global Breast Cancer Statistics, 2012 22 3.1.1 The Leading 50 Countries in Breast Cancer Incidence 24 3.2 Breast Cancer Occurrence in the U.S. 25 3.2.1 Probability of U.S. Women for Being Diagnosed with Breast Cancer 25 3.2.2 Breast Cancer by Age in the U.S. 26 3.2.3 Breast Cancer by Age and Ethnicity in the U.S. 26 3.2.4 Geographic Differences in Breast Cancer Rates in the U.S. 27 3.2.5 Changing Trends in In Situ Breast Cancer 29 3.2.6 Changing Trends in Invasive Breast Cancer in the U.S. 29 3.2.7 Breast Cancer in the U.S. by Race and Ethnicity 30 3.2.8 Breast Cancer in the U.S. by Tumor Size 31 3.2.9 Breast Cancer Mortality Rate in the U.S. 34 3.2.10 Incidence and Mortality Trends in Men 34 3.2.11 Factors Influencing Breast Cancer Survival in the U.S. 35 3.2.12 Five-Year Relative Survival Rate in the U.S. by Stage at Diagnosis 35 3.2.13 Five-Year Survival Rate by Race/Ethnicity and Socioeconomic Factors in the U.S. 36 3.2.14 Five-Year Cause-Specific Survival Rate in the U.S. by Race/Ethnicity 37 3.3 Breast Cancer in Canada 38 3.3.1 Breast Cancer Incidence in Canada by Age, 2012 39 3.3.2 Breast Cancer Mortality in Canada 40 3.3.3 Incidence and Mortality Rates for Breast Cancer in Canadian Women 40 3.3.4 The Five-Year Relative Survival Ratio in Canada 41 3.3.5 Age-Standardized Incidence Rates of Ductal and Lobular Breast Cancer in Canada 42 3.4 Breast Cancer in the U.K. 42 3.4.1 Breast Cancer by Age in the U.K. 43 3.5 Breast Cancer Mortality in OECD Countries 44 3.5.1 Relative Survival Rates from Breast Cancer in OECD Countries 46 3.6 Breast Cancer in Australia 47 3.6.1 Incidence of Breast Cancer by Age in Australia 47 3.6.2 Projected Female Breast Cancer Diagnosis in Australia, 2020 49 3.6.3 Risk of Being Diagnosed with Breast Cancer in Australia 50 3.6.4 Most Common Types of Breast Cancers in Australia 50 3.6.5 Age at Diagnosis by Histological Type in Australia 51 3.6.6 Most Frequently Recorded Anatomical Location of Breast Cancer 51 3.6.7 Ductal Carcinoma In Situ in Australia 52 3.6.8 Incidence of DCIS by Age in Australian Women 53 3.6.9 Female Breast Cancer Mortality in Australia by Age 53 3.6.10 Projections of Female Breast Cancer Mortality in Australia 54 3.6.11 Survival after Diagnosis of Female Breast Cancer in Australia 55 3.6.12 Hospitalizations for Female Breast Cancer in Australia 55 3.7 Breast Cancer in East Asia 56 3.8 Breast Cancer in Western Asia 56 3.9 Breast Cancer Mortality in Korea 57 3.10 Age-Specific Incidence of Breast Cancer in Japan 58 3.11 Age-Specific Breast Cancer Rate in China 58 3.12 Breast Cancer in Young Asian Women 59 4. Emerging Technologies in Breast Imaging 604.1 The Gold Standard: Full-Field Digital Mammography 604.2 Tomosynthesis/3-D Mammography 624.3 Molecular Imaging 634.4 BSGI 63 5. Mammography: An Overview 66 5.1 Screen-Film Mammography 66 5.2 2D Digital Mammography 67 5.3 3D Digital Mammography 68 5.3.1 Better Visualization in 3D Images 70 5.3.1.1 3D Imaging and Superimposed Breast Tissue 71 5.3.1.2 Status of Tomosynthesis 72 5.3.1.3 Other Companies Working on Digital Breast Tomosynthesis (DBT) 73 5.3.1.4 Features of Hologic Tomosynthesis Unit 73 5.3.1.5 GE Tomosynthesis 73 5.3.1.6 Siemens Tomosynthesis 73 5.3.1.7 Philips (Sectra) Tomosynthesis 73 5.3.2 Difference between 3D and 2D Digital Mammography 74 5.3.2.1 Comparative Merits of Digital and Film-Screen Mammography 74 5.4 Basic Physics of Mammography 75 5.4.1 Mammography X-Ray Tubes 75 5.4.2 Mammography Image Receptors 77 5.4.3 Mammography AEC 79 5.4.4 Mammography Scatter Reduction 79 5.4.5 Differences in Dose Levels among Digital Mammography Systems 79 5.4.6 The Irish Study 79 5.4.7 Patient Radiation Doses in Swedish Screening Program 80 5.5 Points to be Considered Before Buying a Mammography System 81 5.6 Cost Containment in Mammography Systems 82 6. Screening Mammography Data from Selected Countries 846.1 U.S. Data on Screening Mammography 846.1.1 Prevalence of Mammography in the U.S. 846.1.2 Drop in U.S. Mammography Rates 846.1.3 Guidelines for Screening Mammography in the U.S. 856.1.4 Crisis in U.S. Mammography Services 856.1.5 Current Mammography Use in the U.S. 876.2 Organized Screening Programs in Canada 896.2.1 Early Detection of Breast Cancer in Canada 896.2.2 Distribution of Breast Cancer Detected during Screening by Stage in Canada 916.2.3 Newly Diagnosed Women with Her2+ by Province in Canada 916.2.4 Breast Cancer Treatment after Diagnosis in Canada 926.2.5 Radiation Therapy after Diagnosis in Canada 936.2.6 Chemotherapy after Breast Cancer Screening in Canada 936.2.7 Screening Mammography in British Colombia (BC) 946.2.7.1 Annual Screening Volume in BC 946.2.7.2 Bilateral Mammography Utilization in BC 966.2.7.3 Histologic Features of Breast Cancers Detected by SMP in BC 966.3 European Data on Screening Mammography 966.3.1 Screening Mammography Rates in OECD Countries 1006.3.2 Screening Mammography in the U.K. 1026.3.3 Screening Activity in the U.K. 1026.3.4 Acceptance of Screening Invitation by Age—All Invitation Types in the U.K. 1026.3.5 Acceptance by Type of Screen in the U.K. 1036.3.6 Screening Quality—First Screen after First Invitation in the U.K. 1036.3.7 Screening Quality—Subsequent Screening in the U.K. 1036.3.8 Screening—Women Aged 71 and Over in the U.K. 1046.3.9 Assessment Outcomes—Age 50-70 in the U.K. 1046.3.10 Assessment Outcomes—Age 45-74 in the U.K. 1056.3.11 Treatment of Screen Detected Breast Cancer in the U.K. 1056.3.12 Immediate Reconstruction after Mastectomy in the U.K. 1066.4 Screening Mammography in Korea 1076.5 Screening Mammography in Japan 1076.6 National Mammography Screening Program in Israel, 2010 1086.7 Mammography in Australia 1096.7.1 MBS-Funded Mammography in 2011 1106.7.2 Differences in Mammography Services by Age in Australia 1116.7.3 Hospitalizations for Female Breast Cancer in Australia 1116.7.4 Most Commonly Undertaken Female Breast Cancer Procedures in Australia 112 7. Mammography: Market Analysis 113 7.1 Global Market for Mammography Equipment 113 7.1.1 Global Market for Full-Field Digital Mammography Systems 114 7.1.2 Leading Vendors in Mammography Sector 115 7.2 U.S. Market for Full-Field Digital Mammography 115 7.2.1 Decline in the Number of Mammography Facilities and Units in the U.S. 116 7.2.2 Growth in Number of Digital Mammography Facilities in the U.S. 117 7.3 Rest of the World Market for Digital Mammography 118 7.4 Mammography Systems Market in Europe 119 8. Profiles of Market Leaders in Mammography 1218.1 Fujifilm U.S.A., Inc. 1218.1.1 Amulet f/Amulet s 1218.1.2 Fuji's 3D Mammography Viewer 1218.2 GE Healthcare Ltd. 1228.2.1 SenoBright 1228.2.2 Senographe Essential 1228.2.3 Senographe Essential e 1238.2.4 Senographe Care 1238.2.5 Senographe DS 1248.2.6 GE's Mammography Workstations 1248.3 Hologic, Inc. 1248.3.1 Selenia Dimension 3D 1258.3.2 Selenia Dimensions 2D 1258.3.3 SecurView 1268.3.4 SecurXchange Archiving Solution 1268.3.5 M-Series (Analog) 1268.3.5.1 StereoLoc 1268.3.5.2 Affinity 1278.4 Philips Healthcare 1278.4.1 MammoDiagnost (Analog) 1278.4.2 MammDiagnost DR 1288.4.3 MammoDiagnost with PCR Eleva 1288.5 Siemens Healthcare 1288.5.1 Mammomat 3000 Nova 1298.5.2 Mammomat 1000 1298.5.3 Syngo MammoReport 129 Appendix 1: Timeline of Advances Against Breast Cancer 130 Appendix 1.1: Timeline 130 Appendix 2: A Woman's Guide to Breast Cancer 138 Appendix 2.1: Breast Biopsy 138 Appendix 2.2: Staging of Breast Cancer 139 Appendix 2.3: Treatment Options 141 Appendix 3: A Women's Guide to Mammograms 146 Appendix 4: A Voice against Screening Mammography 151 Appendix 5: Performance of Tomosynthesis in Different Breast Compositions and Lesion Types 153 Appendix 5.1: Improved Sensitivity 154 Appendix 5.2: Reduced Recall Rate 154 Appendix 5.3: Greater Performance Using Two-View Tomosynthesis 155 Appendix 5.4: Performance of Tomosynthesis in Different Breast Compositions and Lesion Types 155 Appendix 5.5: Performance in Calcifications, Masses and Distortions 155 Appendix 5.6: Performance in Invasive and Non-Invasive Breast Cancers 156 Appendix 5.7: Performance in Fatty and Dense Breasts 156 Appendix 5.8: Tomosynthesis Compared to Ultrasound 157 Appendix 5.9: Tomosynthesis Performance in the Evaluation of Symptomatic Patients 157 Appendix 5.10: Clinical Considerations in Implementing Tomosynthesis 158 Appendix 5.11: One-View vs. Two-View Tomosynthesis 158 Appendix 5.12: Benefits of Combo-Mode Imaging 159 Appendix 5.13: Patient Dose and Risk/Benefit 159 Appendix 6: Cancer Treatment and Survivorship 160 Appendix 6.1: Female Breast Cancer 162 Appendix 6.1.1: Treatment and Survival after Breast Cancer 163 Appendix 6.1.2: Special Concerns of Breast Cancer Survivors 165 Appendix 6.2: Childhood Cancer 165 Appendix 6.3: Colon and Rectum Cancer 166 Appendix 6.4: Leukemias and Lymphomas 169 Appendix 6.5: Lung and Bronchus Cancer 173 Appendix 6.6: Melanoma 175 Appendix 6.7: Prostate Cancer 177 Appendix 6.8: Testicular Cancer 179 Appendix 6.9: Thyroid Cancer 182 Appendix 6.10: Urinary Bladder Cancer 183 Appendix 6.11: Uterine Corpus 185 Appendix 6.12: Challenges for Newly Diagnosed Cancer Patients 187 Appendix 7: U.S. Spending on Cancer 201 Appendix 8: Reimbursement for Screening and Diagnostic Mammography in the U.S. 205 Appendix 8.1: Reimbursement Guidelines for Screening and Diagnostic Mammography 205 Appendix 8.2: Codes and Payment Rates 206 Appendix 8.3: Reimbursement Guidelines for Diagnostic MRI Imaging 207 Appendix 9: Integration of Digital Mammography on PACS 209 Appendix 9.1: Considerations in Deploying Digital Mammography 209 INDEX OF FIGURES Figure 3.1: Breast Cancer Incidence Worldwide 22Figure 3.2: Lifetime Risk of Breast Cancer Worldwide 23 Figure 3.3: Age-Specific Female Breast Cancer Incidence and Mortality Rates in the U.S. 26 Figure 3.4: Female Breast Cancer Incidence and Mortality Rates by Race and Ethnicity in the U.S. 27 Figure 3.5: Incidence Rates of In Situ Breast Cancer by Age in the U.S., 1975-2008 29 Figure 3.6: Incidence Rates of Invasive Breast Cancer by Age, 1975-2008 30 Figure 3.7: Breast Cancer in the U.S. by Race and Ethnicity, 1975-2008 31 Figure 3.8: Breast Cancer Incidence Rates by Tumor Size (=2.0 cm) and Race, 1989-2008 32 Figure 3.9: Localized Breast Cancer Rates in the U.S. by Race, 1976-2008 32 Figure 3.10: Breast Cancer Rate (Tumor Size = 2.1-5.0 cm) in the U.S., 1989-2008 33 Figure 3.11: Breast Cancer Rate (Regional Stage) in the U.S., 1976-2008 33 Figure 3.12: Breast Cancer Death Rate in the U.S. by Race and Ethnicity, 1975-2007 34 Figure 3.13: Trend in Male Breast Cancer Incidence and Mortality in the U.S., 1975-2008 35 Figure 3.14: Five-Year Relative Survival Rate by Stage at Diagnosis and Race 36 Figure 3.15: Breast Cancer Five-Year Relative Survival Rate by Race, 1975-2007 37 Figure 3.16: Percent of All Estimated Cancer Cases in Canadian Women, 2012 39 Figure 3.17: Age-Standardized Incidence and Mortality Rates of Breast Cancer in Canada, 1992-2007 41 Figure 3.18: Five-Year Relative Survival for Breast Cancer by Age Group in Canada, 2005 and 2007 41 Figure 3.19: Age-Standardized Incidence Rates of Ductal and Lobular Cancer in Canada, 1992-2007 42 Figure 3.20: Number of New Breast Cancer Cases per Year and AS Rate in the U.K., 2009 44 Figure 3.21: Female Breast Cancer Mortality Rate in OECD Countries, 2000 and 2009 45 Figure 3.22: Breast Cancer Five Year Relative Survival Rate in OECD Countries, 1997-2009 46 Figure 3.23: Incidence of Breast Cancer by Age at Diagnosis, Females, Australia, 2008 47 Figure 3.24: Incidence of Female Breast Cancer in Australia, 1982-2008 48 Figure 3.25: Incidence of Female Breast Cancer by Age at Diagnosis in Australia, 1982-2008 49 Figure 3.26: Incidence of Female Breast Cancer in Australia, 2000-2020 49 Figure 3.27: Incidence of Ductal Carcinoma In Situ in Australia, 2000-2008 52 Figure 3.28: Incidence of Ductal Carcinoma by Age in Australian Women, 1997-2008 53 Figure 3.29: Female Breast Cancer Incidence and Mortality in Australia by Age, 2008 54 Figure 3.30: Projected Mortality from Female Breast Cancer in Australia, 2000-2020 54 Figure 3.31: Incidence of Breast Cancer in East Asia 56 Figure 3.32: Incidence of Breast Cancer in Western Asia 57 Figure 3.33: Breast Cancer Mortality in Korea, 1985-2020 57 Figure 3.34: Age-Specific Incidence of Breast Cancer in Japan 58 Figure 3.35: Age-Specific Breast Cancer Incidence Rate in China 59 Figure 5.1: Tissue Superimposition Hiding Pathologies in 2D 69 Figure 5.2: Minimizing the Effects of Structure Overlapping within the Breast by 3D 69 Figure 5.3: Schematic of Tomosynthesis 70 Figure 5.4: A Suspicious Area in the 2D Mammography Image 70 Figure 5.5: The 2D Image Next to One Slice of 3D Image Set Showing a Clear Difference 71 Figure 5.6: A 2D Image with a Suspicious Area, Next to a 3D Image Set 71 Figure 5.7: Another 3D Image from the Set Showing that the Suspicious Area is Nothing More than Normal Breast Structures Overlapping 72 Figure 5.8: Detection of Micro-Papillary Type Ductal Carcinoma In Situ in 65 Year Old Woman by 3D 72 Figure 5.9: Comparison of Digital and Film-Screen Breast Images 75 Figure 5.10: X-Ray Energy Spectra for (a) a Mo Anode XRT and (b) with the Addition of 30 µm Thickness of Mo Filtration 76 Figure 5.11: A Mammographic XRT with Collimation and Breast Support 76 Figure 5.12: (a) A Large Phosphor Screen Coupled to Several OCDs Using Fiber Optic Tapers (b) A Scanning-Slot System Where a Narrow Phosphor Screen is Coupled by the Fiber Optics to a Few CCDs and the XRT/Detector is Scanned Across the Anatomy 77 Figure 5.13: Illustration of Scanned-Slot Digital Mammography 78 Figure 5.14: The Average MGD per Exposure for Different Models of FFDM in both Screening and Clinical Mammography 81 Figure 6.1: U.S. Mammography Units and Facilities, 2000-2011 86 Figure 6.2: Mammography Use Among Women 40 Years of Age and Over by Age in the U.S., 2000-2010 87 Figure 6.3: Percentage of Women (Aged 50-69) Who Participated in an Organized Program in the Past Two Years by Province, 2009-2010 89 Figure 6.4: Distribution by Stage at Diagnosis of Women Diagnosed with Invasive Breast Cancer in Canada by Province, 2010 90 Figure 6.5: Distribution by Stage at Diagnosis of Women Diagnosed with Breast Cancer in Canada, 2010 91 Figure 6.6: Percentage of Women Tested as Her2+ by Province in Canada, 2010 91 Figure 6.7: Percentage of Mastectomies by Province in Canada, 2009-2010 92 Figure 6.8: Percentage of Breast Cancer Patients Receiving Radiation Therapy, Started Within Two Years of Diagnosis by Province in Canada, 2009 93 Figure 6.9: Percentage of Breast Cancer Patients Receiving Chemotherapy Started Within One Year of Diagnosis by Province in Canada, 2009 94 Figure 6.10: SMP Annual Screening Volume in BC, 2006-2010 95 Figure 6.11: Bilateral Utilization of Mammography by Women Ages 50-69, 2008-2010 95 Figure 6.12: Breast Cancer Screening at Least Once in Life in Europe (Age 50 to 69), 2010 97 Figure 6.13: Breast Cancer Screening at Least Once in Life in Europe (Age 50), 2010 97 Figure 6.14: Proportion of European Women having Undergone Breast Cancer Screening by Frequency, 2010 98 Figure 6.15: European Participation in Mammography Screening by National Program and Other, 2010 99 Figure 6.16: European Participation in Breast Cancer Screening (Age 50-69) by Educational Status, 2010 99 Figure 6.17: European Participation in Breast Cancer Screening by Income Quintile, 2010 100 Figure 6.18: Percentage of Women Aged 50 to 69 Screened in OECD Countries, 2000-2009 101 Figure 6.19: Treatment of Screen Detected In Situ Non-Invasive and Micro-Invasive Breast Cancer in the U.K. 105 Figure 6.20: Treatment of Screen Detected Invasive Breast Cancer in the U.K. 106 Figure 6.21: Reconstruction after Mastectomy in the U.K., 2009-2010 106 Figure 6.22: Breast Cancer Screening Rates in Korea, 2004-2007 107 Figure 6.23: Participation in Breast Cancer Screening by Age in Japan, 2007 108 Figure 6.24: Participation in BreastScreen Australia by Women Aged 50-69, 2000-2010 110 Figure 6.25: MBS-Funded Mammography Services by Age Group in Australian Women, 2011 111 Figure 7.1: Global Market for Mammography Systems, 2011-2018 113 Figure 7.2: Global Market for FFDM Mammography Equipment, 2011-2018 114 Figure 7.3: Global Market Leaders in Mammography Equipment Market, 2011 115 Figure 7.4: U.S. Market for Full-Field Digital Mammography Market, 2011-2018 116 Figure 7.5: U.S. Mammography Units and Facilities, 2000-2011 117 Figure 7.6: Growth in Number of FFDM Units and Facilities in the U.S., 2004-2010 118 Figure 7.7: Rest of the World Market for Mammography Equipment, 2011-2018 119 Figure 7.8: European Market for Mammography System, 2011-2018 120 Figure A2.1: Tumor Sizes 140 Figure A5.1: Improvement in Cancer Detection 154 Figure A5.2: Increased Breast Cancer Detection Using Tomosynthesis 155 Figure A5.3: Reduced Recall Rates 155 Figure A5.4: Added Value for Calcifications 156 Figure A5.5: Value of Tomosynthesis in Fatty Breasts 157 Figure A5.6: Greater Perception of Extent of Disease Using Tomosynthesis 158 Figure A5.7: Two-View Tomosynthesis Optimizes Chance for Cancer Detection 158 Figure A5.8: Dose Levels of 2D and Tomo Exams Compared to Natural Background Radiation 159 Figure A6.1: Breast Cancer in the U.S. by Race and Stage at Diagnosis 162 Figure A6.2: Female Breast Cancer Treatment Patterns by Stage 163 Figure A6.3: Five-Year Survival Rates for Breast Cancer Patients by Race and Stage at Diagnosis 164 Figure A6.4: Distribution of Colon and Rectum Cancer by Race and Stage at Diagnosis 167 Figure A6.5: Colon Cancer Treatment Patterns by Stage 167 Figure A6.6: Rectal Cancer Treatment Patterns by Stage 168 Figure A6.7: Five-Year Survival Rates for Colon and Rectal Cancer Patients by Race and Stage at Diagnosis 169 Figure A6.8: Distribution (%) of Non-Hodgkin Lymphoma Patients by Race and Stage at Diagnosis 170 Figure A6.9: Chemotherapy Use among Leukemia Patients by Age 171 Figure A6.10: Non-Hodgkin Lymphoma Treatment Patterns 172 Figure A6.11: Distribution (%) of Lung and Bronchus Cancer by Race and Stage at Diagnosis 173 Figure A6.12: Non-Small Cell Lung Cancer Treatment Patterns by Stage 174 Figure A6.13: Five-Year Survival Rates for Lung and Bronchus Cancer Patients by Race and Stage 175 Figure A6.14: Distribution (%) of Melanoma by Race and Stage 175 Figure A6.15: Five-Year Survival Rates for Melanoma Patients by Race and Stage 176 Figure A6.16: Distribution of Prostate Cancer by Race and Stage 177 Figure A6.17: Prostate Cancer Primary Treatment Patterns by Age 178 Figure A6.18: Five-Year Survival Rates for Prostate Patients by Race and Stage 179 Figure A6.19: Distribution of Testicular Cancer by Race and Stage 179 Figure A6.20: Treatment Patterns for Testicular Cancer Patients 180 Figure A6.21: Treatment Patterns for Non-Seminomatous Testicular Cancer 181 Figure A6.22: Five-Year Survival Rates for Testicular Cancer Patients by Race and Stage 181 Figure A6.23: Distribution of Thyroid Cancer by Race and Stage 182 Figure A6.24: Five-Year Survival Rates for Thyroid Cancer Patients by Race and Stage 183 Figure A6.25: Distribution of Urinary Bladder Cancer by Race and Stage 184 Figure A6.26: Muscle Invasive Bladder Cancer Treatment Patterns 184 Figure A6.27: Five-Year Survival Rates for Urinary Bladder Cancer Patients by Race and Stage 185 Figure A6.28: Distribution of Uterine Corpus Cancer by Race and Stage 186 Figure A6.29: Uterine Cancer Treatment Patterns by Stage 186 Figure A6.30: Five-Year Survival Rates for Uterine Corpus Cancer Patients by Race and Stage 187 Figure A6.31: Domains of Quality of Life 193 Figure A6.32: Observed-to-Expected Ratios for Subsequent Cancers by Site, Sex and Age 20 and Older 196 Figure A6.33: Observed-to-Expected Ratios for Subsequent Cancers by Primary Site 198 Figure A6.34: Unmet Caregiver Needs by Time Since Diagnosis 199 Figure A7.1: Estimates of National Expenditures for Cancer Care in 2010 by Site 201 Figure A7.2: National Expenditure for Cancer Care in 2010 by Site and Phase of Care 202 Figure A7.3: Proportion of National Expenditure for Cancer Care in 2010 by Site and Phase of Care 203 Figure A7.4: Percentage of Medicare Payments in the First Year Following Diagnosis for Cancer Care by Type of Service in 2002 204 Figure A9.1: Workflow Using Philips' iSite Radiology for Mammography SCR 210 Figure A9.2: Workflow Using Third Party Workstation for Mammography SCR 211 INDEX OF TABLES Table 3.1: The Top 50 Countries with Leading Breast Cancer Rates 24Table 3.2: Estimated New Female Breast Cancer Cases and Death by Age in the U.S., 2011 25 Table 3.3: Probability of U.S. Women fore Being Diagnosed with Breast Cancer 25 Table 3.4: Female Breast Cancer Incidence and Mortality Rates by Race, Ethnicity and State 28 Table 3.5: Five-Year Cause-Specific Survival Rate by Race/Ethnicity 38 Table 3.6: New Breast Cancer Cases Diagnosed in Canadian Women, 2012 39 Table 3.7: New Breast Cancer Cases Diagnosed in Canada by Age Group, 2012 39 Table 3.8: Breast Cancer Mortality Rates in Canada, 2012 40 Table 3.9: Breast Cancer Incidence Rates per 100,000 Populations in the U.K., 2009 43 Table 3.10: Number of Breast Cancer Patients in the U.K., 2009-2010 43 Table 3.11: The Five Most Commonly Diagnosed Cancers, Females, Australia, 2008 47 Table 3.12: Risk and Average Age at Diagnosis of Female Breast Cancer in Australia, 1982-2008 50 Table 3.13: Incidence and Average Age at diagnosis by Type of Breast Cancer in Australia, 2008 51 Table 3.14: Incidence by Histological Type and Age at Diagnosis in Australia, 2008 51 Table 3.15: Incidence of Breast Cancer by Anatomical Location in Australia, 2008 52 Table 3.16: Relative Survival from Female Breast Cancer in Australia, 2006-2010 55 Table 3.17: Hospitalization for Female Breast Cancer in Australia, 2009-2010 55 Table 3.18: Breast Cancer in Asian Younger Women 59 Table 5.1: DR System Comparisons 68 Table 5.2: Average Mean Glandular Dose per Exposure According to Model 80 Table 5.3: Examination Dose According to Model 80 Table 5.4: Average MGD per Exposure in Screening and Clinical Use for Various Mammography Technologies and Vendors of FFDM 81 Table 6.1: Mammography Screening Prevalence Among Women 40 and Older in the U.S., 2010 84 Table 6.2: Mammography Screening Prevalence by Age and Poverty Status in the U.S., 1987-2010 85 Table 6.3: Certified Mammography Facilities and Accredited Units in the U.S., 2000-2011 86 Table 6.4: Prevalence of Screening Mammography in the U.S. by State, 2010 87 Table 6.5: Histologic Features of Breast Cancers Detected by SMP in BC, 2009 96 Table 6.6: Breast Cancer Screening Activity in the U.K., 2008-2010 102 Table 6.7: Acceptance of Breast Screening Invitations by Age—All Invitation Types 102 Table 6.8: Acceptance by Type of Screen: Women Aged 45-74 103 Table 6.9: Screening Quality—First Screen after First Invitation 103 Table 6.10: Screening Quality—Subsequent Screening 104 Table 6.11: Screening—Women Aged 71 and Over in the U.K. 104 Table 6.12: Assessment Outcomes—Age 50-70 104 Table 6.13: Assessment Outcomes—Age 45-74 in the U.K. 105 Table 6.14: Medicare Benefits Schedule-Funded Mammography Services in Australia, 2011 110 Table 6.15: Hospitalization for Female Breast Cancer in Australia, 2009-2010 111 Table 6.16: Same-Day Hospitalizations and Overnight Hospitalizations for Female Breast Cancer in Australia, 2009-2010 112 Table 7.1: Certified Mammography Facilities and Accredited Units in the U.S., 2000-2011 117 Table A2.1: Staging of Breast Cancer 139 Table A6.1: Estimated Number of Cancer Survivors in the U.S. as of January 1, 2012 160 Table A6.2: Estimated Numbers of U.S. Cancer Survivors by Site as of January 1, 2012 161 Table A6.3: Estimated U.S. Cancer Survivors by Sex and Time since Diagnosis as of January 1, 2012 161 Table A6.4: Estimated U.S. Cancer Survivors by Sex and Age as of January 1, 2012 162 Table A8.1: Mammography Reimbursement Rates—All Sites of Services 206 Table A8.2: Reimbursement for Breast MRI—Hospital Outpatient 207 Table A8.3: Reimbursement for MRI Breast Imaging—Offices and Imaging Centers/Physician 208 To order this report:Medical_Imaging Industry: Mammography World Markets Contact
SOURCE Reportlinker Web 2.0 Latest News
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
|
SYS-CON Featured Whitepapers
Most Read This Week
|